TECH vs TEM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Bio-Techne exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.17. However, there is a massive disconnect between the current price ($60.58) and deterministic value metrics, such as the Graham Number ($12.40) and Intrinsic Value ($10.94). While the PEG ratio of 0.76 and forward P/E of 27.99 suggest growth potential that justifies a premium, stagnant revenue growth (-0.40%) and bearish technical trends temper the outlook. The stock is a high-quality company trading at a significant growth premium.
Tempus AI exhibits critical financial fragility, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across profitability and operational efficiency. While the company demonstrates explosive revenue growth of 83% YoY, this is offset by deep negative margins and a high Debt/Equity ratio of 2.70. The bearish outlook is further reinforced by aggressive insider selling, including significant divestments by the CEO and CFO, and a technical trend score of 0/100. Despite analyst optimism, the fundamental health metrics suggest a high-risk profile.
Compare Another Pair
Related Comparisons
TECH vs TEM: Head-to-Head Comparison
This page compares Bio-Techne Corporation (TECH) and Tempus AI, Inc. (TEM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.